-+ 0.00%
-+ 0.00%
-+ 0.00%
Xinlitai announced that the company successfully renewed their contracts with Foritan® and Xinlitine, and successfully negotiated new indications for Enalol®. They all remained in the 2026 edition of the national health insurance catalogue, and the medical insurance categories were all Class B. The Forlitan® and Cinritine agreement is valid from January 1, 2027 to December 31, 2028, and the Enalol® agreement is valid from January 1, 2027 to December 31, 2027. The new medical insurance catalogue will be officially implemented on January 1, 2027. This matter will not have a significant impact on the company's performance during the reporting period.
Share
Listen to the news
Xinlitai announced that the company successfully renewed their contracts with Foritan® and Xinlitine, and successfully negotiated new indications for Enalol®. They all remained in the 2026 edition of the national health insurance catalogue, and the medical insurance categories were all Class B. The Forlitan® and Cinritine agreement is valid from January 1, 2027 to December 31, 2028, and the Enalol® agreement is valid from January 1, 2027 to December 31, 2027. The new medical insurance catalogue will be officially implemented on January 1, 2027. This matter will not have a significant impact on the company's performance during the reporting period.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending